Home About Us Products Clinical Trials News Investors Contact Senior Management Olav Hellebo Chief Executive Officer Olav Hellebø was appointed to the Board in September 2014. Prior to ReNeuron, he held the role of CEO at Clavis Pharma ASA, a Norwegian, oncology-focused, listed biotechnology company. He joined Clavis from UCB where he built the global organisation responsible for the successful registration and launch of the anti-TNF Cimzia... Read more... Dr Richard Beckman Chief Medical Officer Dr Richard Beckman was appointed Chief Medical Officer in April 2018. Prior to joining ReNeuron, Dr Beckman was the Chief Medical Officer of several innovative biotech and device firms, including Clearside, Ophthotech and Neurotech. Prior to that, he had leadership roles at Alcon, Lux Bio, Becton Dickinson and Allergan. <... Read more... Suzanne Hancock Head of Operations Suzanne Hancock was appointed Head of Operations in July 2020, having joined ReNeuron as a Programme Manager in 2017. Suzanne has broad experience of both leadership and technical scientific roles. She joined ReNeuron from GE Healthcare, where she spent almost twelve years and held a number of managerial roles forming and lea... Read more... Catherine Isted ACMA Chief Financial Officer Catherine Isted was appointed to the Board in October 2021. Catherine joined ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where she was part of the finance leadership team heading up the Corporate Development and IR, helping the business grow over 800%, enter the FTSE250 a... Read more... Prof. Stefano Pluchino Chief Scientific Officer Professor Stefano Pluchino was appointed Chief Scientific Officer in May 2021. He is Reader in Regenerative Neuroimmunology and Honorary Consultant at the University of Cambridge since 2010. He obtained his MD and PhD at the University of Siena, Italy, and progressed to two consecutive post doctorate appointments at the San R... Read more... Shaun Stapleton Vice President Regulatory Affairs and Pharmacovigilence Shaun Stapleton was appointed Head of Regulatory Affairs in June 2015. He joined ReNeuron from Voisin Consulting Life Sciences where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs. <... Read more... Section: About Us About ReNeuron Board of Directors Senior Management Advisory Board Working at ReNeuron Patents Subscribe here for our Press Releases: The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: I agree Click here © ReNeuron Group plc 2021 All rights reserved Website design by Carr Kamasa Design Privacy Notice Disclaimer